165-301: A Phase 3, Open-Label, Randomized, Multi-Center Study to Assess the Safety and Tolerability of an Induction, Titration, and Maintenance Dose Regimen of BMN165 Self Administered by Adults with Phenylketonuria Not.......

Project: Research project

Project Details

StatusFinished
Effective start/end date6/17/13 → 6/15/15

Funding

  • BioMarin Pharmaceutical Inc. (165-301)